NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only

NSABP Foundation, Inc.

General NSABP Information
  Financial Conflicts of
     Interest Policy
  Contact the NSABP

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-51
  Protocol B-52
  Protocol B-53/S1207
  Protocol B-55/BIG 6-13

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR

To report problems, ask
questions or make comments,
please send e-mail to:

NSABP Clinical Trials Overview

Protocol C-09
A Phase III Clinical Trial Comparing Oxaliplatin, Capecitabine and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capecitabine in Patients with Resected or Ablated Liver Metastases from Colorectal Cancer

Specific Aims
Primary Aim
The primary aim of this study is to compare progression-free interval (PFI) between the two treatment groups.

Secondary Aim
The secondary aims of this study are to:
  • compare overall survival and liver PFI between the two treatment groups;
  • assess toxicity in each of the treatment regimens;
  • compare self-reported symptoms between two treatment groups; and
  • compare quality of life in each of the treatment regimens.